

## Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *N Engl J Med* 2012;366:109-19. DOI: 10.1056/NEJMoa1113216.

## **Supplementary Appendix**

Supplement to: Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus Trastuzumab plus Docetaxel in Metastatic Breast Cancer

### **Contents**

Collaborators	page 2
Legend to Supplementary Figure 1	page 3
Supplementary Figure 1	page 4

*The following investigators also participated in the CLEOPATRA study:*

*Argentina* – M.A. Bártoli, M.I. Bianconi, M. Kotliar, J.A. Lacava, M. Matwiejuk, P.E. Price, M. Varela; *Brazil* – J. Andrade, R. Araujo, S. Azevedo, E. Cortes, E. Costa e Silva, D. Cubero, G. Delgado, M. del P. Diz, B. Eyll, F. Franke, R. Hegg, G. Ismael, D. Jendiroba, J.L. Pedrini, R. Pereira, H. Pinczowski, P. Tokunaga, C. Tosello; *Canada* – C. Brezden-Masley; *China* – Ying Cheng, Xuenong Ouyang, Zhenzhou Shen, Xiaojia Wang, Liwei Wang, Tsz Kok Yau, W. Yeo; *Costa Rica* – D. Otero; *Croatia* – Z. Soldic, D. Vrbanec; *Ecuador* – T. Soria; *Finland* – P. Kellokumpu-Lehtinen, S. Pyrhönen; *France* – M. Campone, B. Coudert, J.M. Ferrero, F. Priou; *Germany* – B. Aktas, W. Aulitzky, M. Clemens, E.-M. Grischke, M. Hauschild, M. Just, A. Kirsch, S. Kuemmel, C. Maintz, A. Marmé, V. Mueller, M. Schmidt, A. Schneeweiss, C. Schumacher, C. Thomssen, B. Wesenberg; *Guatemala* – H. Castro-Salguero, C. Hernandez Monroy, L.M. Zelina-Toache; *Italy* – D. Amadori, C. Angiolini, L. Biganzoli, S. Cinieri, T. Gamucci, S. Iacobelli, L. Latini, F. Montemurro, E. Simoncini; *Japan* – K. Aogi, H. Fuji, J. Horiguchi, K. Inoue, Y. Ito, H. Iwata, M. Kashiwaba, N. Kohno, K. Kuroi, N. Masuda, K. Nakagami, T. Nakayama, R. Nishimura, S. Saji, Y. Sasaki, N. Sato, K. Takeda, Y. Tokuda, K. Tsugawa, T. Ueno, J. Watanabe, R. Yoshiaki; *Korea* – Seock-Ah Im, Young-Hyuck Im, Sung Bae Kim, Yong Wha Moon, Jung Sil Ro, Joo Hyuk Sohn; *Latvia* – E. Grincuka, I. Kudaba, G. Purkalne; *Macedonia* – L. Kostovska-Maneva, P. Stefanovski; *Mexico* – G. Martinez, G. Tellez; *Philippines* – P. Caguioa, V. Chan, D. Tudu; *Poland* – M. Foszczynska-Kloda, T. Pienkowski, W. Polkowski, E. Starowska, P. Tomczak; *Russian Federation* – V. Gorbunova, E. Gotovkin, I. Kiselev, M. Kopp, M. Lichinitser, V. Merkulov, L. Roman, V. Semiglazov, V. Shirinkin; *Singapore* – Soo Chin Lee, Zee Wan Wong; *Spain* – E. Alba Conejo, J. Baselga, N. Batista, L. Calvo, E. Ciruelos, J. Cortés, M. Gil i Gil, A. Gonzalez, J. Hornedo Muguero, S. Morales, N. Ribelles Entrena, S. De la C. Sánchez, P. Sanchez Rovira; *Thailand* – W. Arpornwirat, T. Dejthevaporn, J. Maneechavakajorn, V. Srimuninnimit, V. Sriuranpong, P. Sunpaweravong; *UK* – R. Ahmad, L. Assersohn, I. Boiangiu, N. Davidson, C. Gallagher, A. Jones, D. Miles, S. O'Reilly, A. Robinson, D. Wheatley; *USA* – R. Agajanian, J.F. Armor, M.W. Audeh, A.S. Behairy, R. Birhiray, R. Blachly, K. Blackwell, R. Blanchard, P. Blanchet, B.J. Bowers, A. Brufsky, L. Budde, R.R. Carroll, V. Charu, S. Dakhil, B. Daniel, J.A. Ellerton, L. Fehrenbacher, P. Flynn, S. Franco, N. Green, V. Hansen, J. Hargis, C. Hendricks, R.C. Hermann, A. Kallab, M. Karwal, G. Kato, P. Kaufman, P.S. Kennedy, P. Klein, E.P. Lester, C.F. Lobo, R.A. Michaelson, J.A. Neidhart, J.D. Neidhart, A.D. Nguyen, T. O'Rourke, R. Patel, T. Patel, A. Perez, R.G. Quackenbush, C.E. Peterson, J.D. Polikoff, S.J. Prill, R. Robles, G. Rodriguez, F. Senecal, P. Sharma, R. Smith, D. Spicer, S.A. Swain, J.A. Taguchi, C.L. Vogel, D.M. Waterhouse, S. Yadav, D.A. Yardley.

**Supplementary Figure 1. Enrollment, Intent-to-Treat and Safety Populations, and Patient Withdrawals.**

All randomized patients were included in the intent-to-treat population, and patients who received at least one study treatment were included in the safety analysis. Reasons for withdrawals are shown.

